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Introducing tumor-derived cells into normal mammary stem cell niches at a sufficiently high
ratio of normal to tumorous cells causes those tumor cells to undergo a change to normal
mammary phenotype and yield normal mammary progeny. This phenomenon has been
termed cancer cell redirection. We have developed an in vitro model that mimics in vivo redirection of cancer cells by the normal mammary microenvironment. Using the RNA profiling
data from this cellular model, we examined high-level characteristics of the normal, redirected, and tumor transcriptomes and found the global expression profiles clearly distinguish the three expression states. To identify potential redirection biomarkers that cause the
redirected state to shift toward the normal expression pattern, we used mutual information
relationships between normal, redirected, and tumor cell groups. Mutual information relationship analysis reduced a dataset of over 35,000 gene expression measurements spread
over 13,000 curated gene sets to a set of 20 significant molecular signatures totaling 906
unique loci. Several of these molecular signatures are hallmark drivers of the tumor state.
Using differential expression as a guide, we further refined the gene set to 120 core redirection biomarker genes. The expression levels of these core biomarkers are sufficient to make
the normal and redirected gene expression states indistinguishable from each other but radically different from the tumor state.
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under accession # GSE89963.
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Introduction
Cancer initiation and progression is a complex genetic disease where mutations and epigenetic
alterations in cells lead to inactivation of tumor suppression genes, activation of oncogenes,
and impact DNA repair processes [1–2]. The accumulation of genetic mutations often leads to
deregulation of proliferative signaling pathways and suppression of pro-differentiation apoptotic pathways. The differential expression of signaling pathways affects not only the mutated
cells but also impacts surrounding cells through intercellular communication involving
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biophysical and biochemical modes of signaling. Intercellular communication is not a onedirection process, as surrounding cells are known to influence tumor cell activity [3].
Normal mammary microenvironments, or somatic stem cell niches, have been shown to
direct the cell fates of non-mammary stem cells [4–7]. When non-mammary stem cells are
incorporated into reforming mammary stem cell niches during mammary tissue regeneration
the non-mammary stem cells adopt a mammary phenotype and provide progeny to a functional reconstituted mammary gland in vivo. When tumor-derived cells are incorporated into
reforming normal mammary stem cell niches the tumor cells also adopt a normal mammary
phenotype and provide differentiated cell progeny to the normal mammary outgrowth [8–10].
This phenomenon has been termed cancer cell redirection. Cancer cell redirection is determined on the ratio of cancer cells to normal mammary epithelial cells present. Successful redirection of human breast cancer cells and mouse mammary tumor cells occurs at a ratio of 1
cancer cell for every 50 normal epithelial cells while redirection of embryonal testicular carcinoma cells can occur at a ratio of 1 cancer cell for every 10 normal cells. When mouse mammary-tumor derived cells that overexpress erbB2 are redirected, the auto-phosphorylation of
the erbB2 tyrosine kinase is attenuated while total expression of erbB2 is not impacted [11].
Reduced erbB2 phosphorylation is one mechanism involved in cancer cell redirection and
detection of reduced receptor activity serves as a biomarker of cancer cell redirection.
The genetic profiles of insipient cancer cells change from normal expression patterns to
ultimately their cancer cell profile [12]. Breast cancers have been divided into six main groups
based on genetic profiles with additional subgroups being added upon discovery of new
genetic profiles. The six main groups are 1) Luminal A, 2) Luminal B, 3) HER2 enriched, and
4) claudin low, 5) normal-like, and 6) basal-like [13]. Amplification and overexpression of
HER2 is observed in 20–30% of human breast cancers and is inversely correlated with patient
survival [14–16]. Within these complex differential gene expression patterns lie the causal
genetic mechanisms underlying tumorigenesis and possibly cancer cell redirection.
We have developed an in vitro system of cancer cell redirection that employs the 1:50
ratio of erbB2-overexpressing cancer cells to normal cells [11]. This in vitro system has been
validated as an alternative to the in vivo model. Using our in vitro system of cancer cell redirection, we investigated the genetic profiles of erbB2-overexpressing mammary tumor-derived
cells as they undergo the redirection phenomenon. In this report, we present transcriptome
profiling results from multiple mouse sorted cell groups that model normal, redirected, and
tumor states. Then we describe the application of a mutual information approach to identify
relevant molecular signatures (biomarker packages) that appear to be involved in cancer cell
redirection.

Materials and methods
Cell culture
Establishment of the MMTV-neu cell lines is described elsewhere [11]. MMTV-neu cells were
maintained in DMEM supplemented with 10% FBS and 1% antibiotic/antimycotic. COMMA-D cells were grown in DMEM/F12 with 2% FBS, 0.1M HEPES, 1% antibiotic/antimycotic,
10 μg /ml insulin, 5 ng/ml EGF and 4 μg/ml gentamicin added. Co-cultures of MMTV-neu
and COMMA-D cells were grown in COMMA-D medium. All cultures were grown at 37˚C
and 5% CO2.

Magnetic sorting
The protocol used for magnetic sorting is described elsewhere [8]. After 4 days in culture
cells were detached by trypsin, washed once with PBS and resuspended in 100 μl of diluent
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containing primary antibody (1:50; anti-erbB2, Miltenyi) and incubated for 30 min at 4˚C.
The cells were then washed 2 x 10 min and resuspended in 100 μl of diluent containing biotinylated secondary antibody (1:100) and incubated for 15 min at 4˚C. The cells were then
washed 2 x 10 min and resuspended in 80:20 μl mix of diluent and anti-biotin magnetic beads
(Miltenyi) and incubated for 15 min at 4˚C. The cells were then washed 2 x 10 min and resuspended in 500 μl of running buffer and separated through a LS column (Miltenyi). The erbB2-positive and erbB2-depleted fractions were collected (Fig 1A).

RNA isolation
Total RNA was isolated from the sorted samples using an RNAaqueous Micro kit (Ambion,
Austin, TX) that utilizes glass fiber filter column purification. Isolated total RNA was then
treated with DNase (Qiagen, Valencia, CA) to remove any DNA contamination. The concentration of RNA was determined using a NanoDrop and the RNA integrity was analyzed with a
RNA nano chip on a Bioanalyzer (Agilent Technologies, Santa Clara, CA). Total RNA was isolated from three independent experiments performed sequentially.

Microarray analysis
A total of eighteen samples (6 groups in triplicate) were run on Mouse gene 1.0 ST Arrays
from Affymetrix (http://www.affymetrix.com). Samples were RMA normalized and log2 gene
expression matrices processed using R v3.1.2 and the following Bioconductor v3.1 packages
[17]: affy [18], limma [19], and oligo [20] according to standard procedures [21]. The experimental design for differential gene expression with limma was CN = c(0,0,0,1,1,1), TR = c
(1,1,1,0,0,0). Differential gene expression results between all combinations of cell groups are
available in S1 Table. The microarray CEL files were deposited in the NCBI GEO database
under accession # GSE89963.

Fig 1. The experimental system and global gene expression pattern. A: The experimental system consists of six cell
groups; normal (A) and tumor (B) cells were mixed in either a 1:1 or 50:1 (normal:tumor) ratio and cultured for 4 days, then
magnetically sorted based on expression of erbB2 into four resultant groups: normal (D) or tumor (F) from the 1:1 mixing
and normal (C) and redirected tumor (E) from the 50:1 mixing; B: Heatmap of all transcripts present in the microarray, log2
expression values normalized by column; columns are identified at the bottom of the figure with their cell group classification
and replicate number.
https://doi.org/10.1371/journal.pone.0179265.g001
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qRT-PCR validation
To validate microarray results we selected three genes: AREG, ERBB2, and THBS1 for
qRT-PCR analysis. The housekeeping gene GAPDH was used as a reference gene to normalize
the expression of each test gene. Primers used for each gene are listed in S2 Table. RNA was
reverse-transcribed to cDNA using the Ambion Retroscript kit two-step protocol. The quantity and quality of the RNA was determined using a Nanodrop 2000. The cDNA was analyzed
using the QuantiTech SYBR Green RT-PCR Kit (Qiagen, Valencia, CA) on the Step One Plus
(Applied Biosystems, Grand Island, NY). Relative expression was determined using the ΔΔCt
method with GAPDH as the reference gene. Results of the validation are presented in S1 Fig.

Data analysis
Data was collected as RNA sequence microarray measurements from three repeated experiments involving six cell groups, A—F (Fig 1A). The RNA normalized gene expression matrix
(GEM; available accession # GSE89963) consisted of intensity measurements of 35,556 probe
sets for the cell groups, three replicates each of A through F, yielding 18 columns. The range of
the data was compressed by log2 transformation, yielding an expression range from 3.582 to
14.052. All calculations were performed in MATLAB. Mutual information (MI), using units of
“bits,” was used to describe the similarity of the cell groups to each other and of subsets of
genes to each other. Here, the term “information” (or alternatively, “entropy”) reflects its
usage in information theory, as a measure of uncertainty about a distribution [21]. Mutual
information is a method of measuring the symmetric dependence of two variables. It is not dissimilar to Pearson’s correlation, in this sense. Unlike Pearson’s correlation however, mutual
information, defined logarithmically, is not limited in its sensitivity to the measurement of linear relationships between groups. [21]. We utilized an existing MI toolbox for MATLAB [22].

Visualization
Cell groups were visualized using classic multidimensional scaling (CMDS) and the cmdscale
function in MATLAB. For this, a dissimilarity matrix (DM) was built based on inverse MI. MI
was calculated for each combination of cell group-replicates, column pairs from the gene
expression matrix (GEM), and maximum entropy for the set size was divided by this MI value
to give a dissimilarity score. CMDS was used to build an approximate picture in 1-dimensional
space of the “spread” of the expression profiles for each cell group and later, to visualize the
relationship, in 3-dimensional space, of the similarity of the cell groups to each other based on
subsets of genes.

Confocal imaging
Cultures were grown on chamber slides and fixed with 4% paraformaldehyde for 10 min at
room temperature, rinsed with PBS then stained using standard protocols. Briefly, the fixed
cells were permeabilized with 0.1% Triton X-100 then blocked using 10% serum. The primary
antibodies used were anti-Mapk1 (1:800), anti-phospho-Neu (1:50)(Santa Cruz Biotech), antiNotch2 (1:200)(Cell Signaling Technologies); each was applied and incubated overnight at
4˚C. Secondary antibodies were conjugated to Alexa 488 or Alexa 568 (1:200)(Life Technologies) and incubated for 60 min at room temperature. Slides were coverslipped with ProLong
Antidfade mounting media containing DAPI (Life Technologies). Images were collected using
a Leica TCS SPE confocal microscope at the same laser and acquisition setting. To ensure the
laser power and imaging settings were not acquiring autofluoresence, a comparison image was
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generated from using an unstained sample. Images were analyzed using Image J and Adobe
Photoshop.

Western blotting
Protein lysates were collected using M-PER mammalian protein extraction reagent with protease and phosphatase inhibitors added (Thermo Scientific; Rockford, IL). Lysates were cleared
at 10,000 rpm for 10 min at 4˚C then transferred to new tubes and frozen at -20˚C until analysis. Protein concentration was determined using a BCA assay. Samples were combined with
sample running buffer and boiled for 10 min. Proteins were separated on a 4–20% gel, transferred to nitrocellulose then probed using anti-β-actin and anti-Notch2 followed by HRP-conjugated secondary antibodies (all Cell Signaling Tech). Target proteins were detected using the
chemiluminescent reagent Lumiglo (Cell Signaling) and visualized using FluorChemM (Cell
Biosciences; Wallingford, CT).

Results
Sample collection
Mammary tumor-derived cells that overexpress erbB2 were co-cultured with normal mammary epithelial cells in our in vitro model of cancer cell redirection. The different ratio cultures
were magnetically sorted into erbB2+ and erbB2- fractions (Fig 1A). Each fraction was assigned
a Group designation (A-F) (Fig 1A). RNA collected from each fraction was then arrayed. Generated heatmaps of all transcripts are presented in Fig 1B.

MI-based molecular signature discovery
In the interest of exploring the behavior of genes with shared action, 13,311 gene lists, or
molecular signatures, from the Broad Institute Molecular Signatures Database were evaluated.
To transform the molecular signatures to sets of values from the gene expression matrix
(GEM), each signature was translated first into official gene identifiers that were translated
into probe set identifiers in the GEM. Not all genes in all molecular signatures were represented in our GEM. This gave each molecular signature represented by an N x 18 expression
matrix, a subset of the GEM. Molecular signatures with gene membership N of 10 or fewer
were excluded as being too small to demonstrate reliable mutual information (MI) measurements (Fig 2). Only sets of a size equal to or greater than the range of the data were included
for consideration. We attempted to extend each molecular signature by inputting the sets into
genemania.org and filtering linked genes by genetic, physical, and co-expression gene interactions. The extended molecular signatures sets are available in S3 Table. Molecular signatures
that maximized the ratio of MI between normal and redirected cell groups (groups A and E) to
MI between redirected and tumor cell groups (E and B) were determined by this equation:
MIðA; EÞ
MIðE; BÞ
This ratio was calculated for each molecular signature to build a distribution of such values.
A significance threshold was defined using the Bonferroni correction [23]. The molecular signatures were filtered by minimum size and those with MI(A,E)/MI(E,B) of zero were excluded.
Of the 13,311 molecular signatures, 12,527 remained after this filtering. Bonferroni correction
yielded a significance threshold of 7.983 x 10−7. This corresponded to a lowest significant MI
ratio value of 5.817. Molecular signatures whose MI ratio values were above or equal to this
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Fig 2. Mutual information performance and set size. MI and entropy for molecular signatures of increasing size. Points
in black represent maximum entropy for a given set size–maximum possible information; points in red are MI values of
random samples sets from columns A1 and A2 of the GEM (likely to be more similar as they belong to the same cell group);
blue measurements are from columns A1 and B1 of the GEM (likely to be less similar); Triangle markers represents the
molecular signature size minimum used in our calculations; molecular signatures below this size were excluded from
consideration. A: zoomed group size 1 to 50; B: a larger plot of group size 1 to 500.
https://doi.org/10.1371/journal.pone.0179265.g002

threshold were selected as pathways statistically significant with respect to tumor cell
redirection.

Visualization
Distributions of expression levels for each cell group showed a remarkable pattern (Fig 3A).
Tumor cell groups (B, F) generally exhibited a single peak while a weakly bimodal shape characterized the distributions of normal (A, C, D) and redirected (E) cell groups (Fig 3B). Using
CMDS, we rendered the distributions in the single dimension of greatest dissimilarity as

Fig 3. Distribution of expression levels for each cell group. A: Expression level distributions ordered in one
dimension on the basis of dissimilarity by mutual information. Yellow = normal (cell group A), orange = redirected (E),
blue = tumor (B). Order of cell group-replicates, from bottom-left to top-right: A3, A1, A2, C3, C2, C1, E2, E3, D3, D2, E1, D1,
F3, F2, F1, B1, B2, B3. B: Expression level distributions for all cell group E replicates (blue) superimposed on distributions
for all B replicates (red).
https://doi.org/10.1371/journal.pone.0179265.g003
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calculated by mutual information (Fig 3A). Note the progressive change in distribution shape
along this axis.

MI-based molecular signature discovery
Mutual information ratios were of interest because information content increases with set size.
By measuring relative relationships in the dataset, we normalized for the effect of set size on
the measurements. We were most interested in the Broad molecular signatures that maximized
MI(A,E)/MI(E,B)–i.e. those that demonstrated high mutual information between cell groups
A and E and low MI between E and B, interpreting these to be pathways that showed similar
patterns of expression in A and E (normal and redirected) and dissimilar patterns of expression in E and B (redirected and tumor).
Based on this ratio, molecular signatures above the threshold of significance were identified.
Of the molecular signatures evaluated, 20 exceeded this threshold on the upper limit of the distribution. Those molecular signatures, which demonstrate the greatest whole-group transformations in expression of redirected cells along the tumor-to-normal spectrum, are listed in
Table 1. MI ratio results for all molecular signatures evaluated are available in S4 Table.
Each of the significant molecular signatures was extended with additional interacting genes,
associated with those already present in the molecular signature. The additional genes were
added on the basis of significant genetic, co-expression, or physical interaction found in the
genemania.org database and significant differential gene expression between cell groups A (normal) and E (redirected) from B (tumor). When MI ratios were calculated for these molecular
signatures extended with differentially expressed (p<0.0001) interacting genes, the effect was an
improvement in MI(A,E)/MI(E,B) in a majority of cases where new genes were incorporated
(REACTOME_SOS_MEDIATED_SIGNALLING,
Table 1. Molecular signatures that demonstrate the greatest MI ratio.
Molecular Signatures

MI Ratio MSDB Description

REACTOME_SOS_MEDIATED_SIGNALING

12.726

Genes involved in SOS-mediated signaling

BIOCARTA_CERAMIDE_PATHWAY

9.050

Ceramide signaling pathway

REACTOME_NOTCH_HLH_TRANSCRIPTION PATHWAY

8.565

Genes involved in Notch-HLH transcription pathway

MOOTH_FFA_OXYDATION

7.557

Genes involved in free fatty acid oxidation

REACTOME_PROCESSIVE_SYNTHESIS_ON_THE_LAGGING_STRAND

7.217

Genes involved in Processive synthesis on lagging strand

LANDIS_BREAST_CANCER_PROGRESSION_LP

7.141

Genes upregulated in preneoplastic mammary tissues

GOTZMANN_EPITHELIAL_MESENCHYMAL_TRANSITION_UP

7.134

Genes upregulated during EMT

INGA_TP53_TARGETS

6.573

Genes with promotors containing TP53 response elements

NIKOLSKY_BREAST_CANCER_21Q22_AMPLICON

6.494

Genes within amplicon 21q22

REACTOME_POL_SWITCHING

6.490

Genes involved in polymerase switching

CROMER_METASTASIS_DN

6.381

Metastatic markers of head and neck cancers

SA_PROGRAMMED_CELL_DEATH

6.331

Genes involved in apoptosis

BOGNI_TREATMENT_RELATED_MYELOID_LEUKEMIA_DN

6.153

Genes down-regulated in ALI

KEGG_SNARE_INTERACTIONS_IN_VESICULAR_TRANSPORT

6.134

Genes involved in SNARE interactions

FLECHNER_BIOPSY_KIDNEY_TRANSPLANT_OK_VS_DONOR_DN

5.964

Genes down-regulared in normal kidneys

MOSERLE_IFNA_RESPONSE

5.842

Upregulated genes in ovarian progenitor cells in response to IFNα

HUANG_DASATINIB_RESISTANCE_UP

5.836

Genes with expression that correlates with dasatinib treatment

KEGG_BASE_EXCISION_REPAIR

5.835

Genes involved in base excision repair

PID_CERAMIDE_PATHWAY

5.824

Genes in the ceramide signaling pathway

MILI_PSEUDOPODIA_CHEMOTAXIS_DN

5.817

Genes down-regulated in response to LPA

https://doi.org/10.1371/journal.pone.0179265.t001
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GOTZMANN_EPITHELIAL_TO_MESENCHYMAL_TRANSITION_UP, INGA_TP53_TARGETS, CROMER_METASTASIS_DN, and MILI_PSEUDOPODIA_CHEMOTAXIS_DN). In
the case of the most improved molecular signature, REACTOME_SOS_MEDIATED_SIGNALLING, the MI ratio was increased from 12.726 to 15.812. Results of this extension for all molecular signatures, at a variety of stringency levels, are available in S5 Table.
We visualized representative molecular signatures with CMDS at either extreme along the
MI(A,E)/MI(E,B) distribution (Fig 4). Molecular signatures with the lowest and highest ratios
correspond to signatures that associate with tumor versus normal states.

Discussion
In this report, we describe the transcriptome profiling of in vitro samples modeling normal,
tumor, and redirected cellular states. This analysis yielded 32,399 differentially expressed transcripts between the six cell states A-F (adjusted p < 0.0001; S1 Table). Each of these single gene
differential expression patterns is interesting and a potential biomarker, especially those transcripts which were significantly different between redirected and tumor states but not between
normal and redirected states. However, we found the large number of relevant transcripts to
be unwieldy, so we chose to approach the biomarker discovery from a polygenic perspective
using curated molecular signature gene sets that were significantly different in terms of mutual
information between redirected and tumor states.
On the path to mutual information-based biomarker discovery, we observed that the global
gene expression distributions were quite interesting. First, we noticed that the normal/

Fig 4. Molecular signature mutual information distinguishes cell groups. The MI(A,E)/MI(E,B) distribution
in the center is for all molecular signatures. The lower ratios to the left of the distribution represent molecular
signatures where the redirected state (E) is closer to the tumor state (B); The higher ratios to the right of the
distribution represent molecular signatures where the redirected state (E) is closer to the normal state (A).
Sample molecular signatures in the 3D insets show cell group replicate differences at percentiles 1, 2, 5 (left
column, bottom to top) and 95, 98, 99 (right column, top to bottom) of the MI ratio distribution. Molecular signature
markers: red markers at the base of the distribution indicate the position of the significant molecular signatures
along the distribution; blue markers and arrows indicate the position of the most adversely affected molecular
signature after the addition of the extended genes (left marker, PID_CERAMIDE_PATHWAY) and the molecular
signature with the most improved ratio after extension (right marker,
REACTOME_SOS_MEDIATED_SIGNALLING).
https://doi.org/10.1371/journal.pone.0179265.g004
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redirected states demonstrated a bimodal distribution suggesting two distinct expression intensity gene populations (Fig 3A). The bimodal distribution dissolves as the expression state
becomes more tumor-like and highly expressed genes shift to a lower expression state. It is possible that this shift is due to an increase in silenced tumor suppressor genes. Second, by determining the distance between global expression distributions with mutual information, we were
able to sort the replicate groups into an alignment that satisfies intuition, where normal (A) and
redirected (E) states are spatially close to each other but distant from tumor (B) states with
some fluctuation in the intermediates, D, C, and F (Fig 3A). Since the global expression patterns
were logical, we were confident that we could detect the specific gene sets underlying the states.
An excellent source of interdependent gene sets exists in the Broad Institute’s Molecular
Signatures (MS) Database. Using the MI(A,E)/MI(E,B) ratio as a metric, we were able to filter
over 13,000 MS down to 20—a manageable gene number that still maintains a significant level
of the polygenic complexity required for tumorigenesis and presumably cancer cell redirection
(Table 1). The sum of genes in these pathways is a collective biomarker set for cancer cell redirection. While the total unique gene count is high (906 genes), this number can be reduced to
core genes that are not differentially expressed in normal (A) and redirected (E) states but are
differentially expressed between normal and tumor (B) states and redirected and tumor states
(107 genes, adjusted p < 0.0001). These core genes can be extended by the addition of 13
more, identified by on the basis of gene interactions, giving a total 120 of these core biomarkers. The full list of these is available in S6 Table. Thus, we have significantly narrowed the
search for genes potentially involved in cancer cell redirection.
Most of the collective function of genes in the 20 signatures make sense in terms of tumor
involvement and are candidate effectors for returning a tumor to a normal state. Eight signatures
are clearly involved in cancer. One signature is involved in general tumorigenesis (INGA_TP53_
TARGETS; 15 genes) and seven others in specific tumor subtypes: GOTZMANN_EPITHEL
IAL_TO_MESENCHYMAL_TRANSITION_UP (66 genes; liver cancer), MOSERLE_IFNA_
RESPONSE (22 genes; ovarian cancer), CROMER_METASTASIS_DN (8 genes; head and neck
cancer), BOGNI_TREATMENT_RELATED_MYELOID_LEUKEMIA_DN (28 genes; leukemia),
LANDIS_BREAST_CANCER_PROGRESSION_UP (42 genes; breast cancer), HUANG_DASATINIB_RESISTANCE_UP (73 genes; breast cancer), and NIKOLSKY_BREAST_CANCER_21Q22_AMPLICON (13 genes; breast cancer). The latter three signatures are of high interest given
the breast cancer model system we are investigating. While a full discussion of this large number
of genes is too vast, we discuss two of the significant signatures in detail below.
The SOS mediated signaling molecular signature (REACTOME_SOS_MEDIATED_SIGNALLING; Table 1) contains a group of genes implicated in the widely investigated RasMek-Erk pathway, a MAPK (mitogen-activated protein kinase) mediated pathway understood
to play a role in cell proliferation and survival. Constitutional activation of this pathway,
because of mutation, is a feature of many cancers [24–25]. Stimulation by a growth factor of a
receptor tyrosine kinase like EGFR or erbB2 enables the subsequent binding of Grb2 and Sos1
to the receptor, beginning a phosphorylation cascade. The finding that the well-characterized
Sos-mediated Ras-Mek-Erk pathway, frequently altered in cancer cells, exhibits the most
extreme MI ratio is a reasonable result. Many genes showed expression levels that were
depressed in tumor cells as compared to normal and redirected samples (Fig 5A). Mapk1
expression was found elevated in Group A and in Group E compared to Group B (Fig 5A).
When cultures were examined for Mapk1 we found high Mapk1 expression in Group A normal cells, very little Mapk1 expression in Group B cancer cells, and differential expression in
1:50 co-cultures (Fig 5C). The normal cells continue to express Mapk1 in the 1:50 co-cultures.
Cancer cells expressed very little Mapk1 in the 1:50 co-cultures (Fig 5C green arrows). Redirected cancer cells expressed Mapk1 (Fig 5C red arrows) thus confirming the genetic data.
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Fig 5. Representative cancer redirection molecular signatures. Markers indicate genes with at least one transcript identified as
significantly differentially expressed. Gene names in gray are those added by interaction with the original molecular signatures members.
Heatmaps for all groups are available in Supplemental Dataset 1. (A) Molecular signature of the SOS mediated signaling pathway. (B)
Molecular signature of the Notch HLH pathway. (C) Immunoflourescent staining of cells for P-erbB2 (green) and Mapk1 (red). Nuclei
counterstained with DAPI. Scale bars = 40 μm. Lower right image is DIC image with Xgal stained lacZ+ cells evident. (D) Western blots probed
for Notch2. β-actin used as loading control. A-Normal cell lysates, B-Cancer cell lysates, E-Lysates from 1:50 cultures.
https://doi.org/10.1371/journal.pone.0179265.g005

The molecular signature with the third highest MI ratio is the Notch-HLH pathway (REACTOME_NOTCH_HLH_TRANSCRIPTION_PATHWAY; Table 1). The Notch family regulates normal development and when expression patterns are altered developmental disorders,
tumor initiation, and cancer progression result. In the normal mouse mammary gland, high
levels of Notch3 and Notch4 are found in the terminal end buds (TEBs) that are present during
ductal morphogenesis [26]. TEBs contain a subpopulation of duct-limited progenitor cells that
also give rise to myoepithelial cells. Notch3 also serves as a marker of luminal progenitor
cells [27]. Activation of Notch1 results in an expansion of mammary luminal progenitor cells
[28]. Notch1 and Notch2 regulate asymmetric division of mammary progenitor cells during
pubertal development [29]. Inhibition of Notch1 reduces cancer stem cell function, reduces
expression of Notch target genes HES1, HES5 and HEY-L, and reduces the population of
CD44HiCD24low, a population identified as cancer stem cells [30–32]. Notch1 was not one of
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the genes identified during analysis (S1 Table). The shift in Notch expression patterns during
redirection is not unexpected as the cells are converting from a tumorigenic phenotype to a
normal developmental phenotype (Fig 5B). Protein analysis revealed Notch2 expressed by
Group A and Group E with lower expression found in Group B (Fig 5D). This result is similar
to the genetic expression data (Fig 5B).
Not only are mouse tumor-derived cells susceptible to redirection [8, 11] but human breast
cancer and embryonic testicular carcinoma cells have been redirected [9–10]. Both human
female and male derived cancer cells differentiated into functional breast epithelial cells in
response to signals from the normal mouse mammary microenvironment [8–11]. This suggests that human cancers are reactive to controlling intercellular signals present in developing
mammalian tissues. The signaling pathways identified here may also be involved in potential
human cancer cell redirection and differentiation.
One limitation of the results outlined within is the presumption that the different behavior
between the normal cells, the cancer cells, and the redirected cells is due to the expression of
specific genes and RNAs. Multiple studies have demonstrated that RNA expression does not
definitively correlate to protein expression. The processes of mRNA decay, translation, and
protein degradation are important factors in addition to mRNA transcription in regards to
steady-state protein expression [33–36].
A second limitation of the data presented here is that it is derived from a single cancer cell
line. The MMTV-neu mouse model is an accepted model of human HER2+ breast cancer [37].
There are numerous subsets of human breast cancer; the six main groups are 1) Luminal A, 2)
Luminal B, 3) HER2 enriched, and 4) claudin low, 5) normal-like, and 6) basal-like [13].
Future studies will examine the profiles of redirected human breast cancer cells in vitro and in
vivo. The human basal-like TNBC cell line MDA-MB-231 has been redirected in vivo so the
models we use are not species limited [10].
In conclusion, to the best of our knowledge, we provide the first transcriptome profiling of
an in vitro model system of cancer cell redirection. Through MI-based gene expression distribution sorting, we observe dramatic differences in global gene expression patterns between
normal and tumor states as well as “movement” of intermediate states including cancer cell
redirection towards the appropriate state (Fig 6). The twenty core molecular signatures we discovered using the MI-ratio approach are exciting candidate biomarker gene sets that could be
controlling cancer cell redirection (Table 1). We are currently porting our system to human
and in vivo systems to further delineate the causal genes that could hold the key to the genetic
mechanism of cancer cell redirection.

Fig 6. Core cancer redirection biomarker set. A: Expression level distributions 120 core genes visualized in 1D using
CMDS; B: Heatmap of significantly differentially expressed transcripts of the 120 core genes.
https://doi.org/10.1371/journal.pone.0179265.g006
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Supporting information
S1 Fig. Validation of qRT-PCR. Real-time PCR validation of 3 target genes, ErbB2, AREG
and THBS1. Relative expression based on expression of GAPDH.
(TIF)
S1 Table. Complete analyses. Differential gene expression analysis between all combinations
of cell groups.
(ZIP)
S2 Table. List of primers. Primers used for gene analysis by quantitative real-time PCR.
(PDF)
S3 Table. Extended genes associated with each of the significant molecular signatures and
the basis of their interaction.
(XLSX)
S4 Table. All molecular signatures evaluated, ordered by decreasing MI(A,E)/MI(E,B) with
member genes and probe set IDs.
(ZIP)
S5 Table. Results of extension of significant molecular signatures on MI(A,E)/MI(E,B) at
several levels of stringency.
(XLSX)
S6 Table. Biomarker set. Genes added by interaction are indicated as well as those identified
as core biomarkers are indicated.
(XLSX)
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